Nuacht

GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment
GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...
Pharmabiz10 uair an chloig
GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease
GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...
GSK (LSE:GSK) Secures FDA Approval For COPD Treatment, Eyes European Nod For Blenrep
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.
Health and Me on MSN13 uair an chloig
FDA Greenlights Nucala as New Treatment for COPD
FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...
Medpage Today on MSN22 uair an chloig
FDA Approves Mepolizumab for COPD
Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...